Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial by Hegi, Monika et al.
ORIGINAL PAPER
Presence of an oligodendroglioma-like component in newly
diagnosed glioblastoma identifies a pathogenetically
heterogeneous subgroup and lacks prognostic value: central
pathology review of the EORTC_26981/NCIC_CE.3 trial
Monika E. Hegi • Robert-Charles Janzer • Wanyu L. Lambiv • Thierry Gorlia • Mathilde C. M. Kouwenhoven •
Christian Hartmann • Andreas von Deimling • Danielle Martinet • Nathalie Besuchet Schmutz •
Annie-Claire Diserens • Marie-France Hamou • Pierre Bady • Michael Weller • Martin J. van den Bent •
Warren P. Mason • Rene´-Olivier Mirimanoff • Roger Stupp • Karima Mokhtari • Pieter Wesseling
Received: 4 December 2011 / Revised: 29 December 2011 / Accepted: 30 December 2011 / Published online: 15 January 2012
 Springer-Verlag 2012
Abstract Glioblastoma (GBM) is a morphologically
heterogeneous tumor type with a median survival of only
15 months in clinical trial populations. However, survival
varies greatly among patients. As part of a central pathol-
ogy review, we addressed the question if patients with
GBM displaying distinct morphologic features respond
differently to combined chemo-radiotherapy with tem-
ozolomide. Morphologic features were systematically
recorded for 360 cases with particular focus on the pres-
ence of an oligodendroglioma-like component and
respective correlations with outcome and relevant molec-
ular markers. GBM with an oligodendroglioma-like
component (GBM-O) represented 15% of all confirmed
GBM (52/339) and was not associated with a more
favorable outcome. GBM-O encompassed a pathogeneti-
cally heterogeneous group, significantly enriched for IDH1
mutations (19 vs. 3%, p = 0.003) and EGFR amplifica-
tions (71 vs. 48%, p = 0.04) compared with other GBM,
while co-deletion of 1p/19q was found in only one case and
the MGMT methylation frequency was alike (47 vs. 46%).
Expression profiles classified most of the GBM-O into two
subtypes, 36% (5/14 evaluable) as proneural and 43% as
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classical GBM. The detection of pseudo-palisading
necrosis (PPN) was associated with benefit from chemo-
therapy (p = 0.0002), while no such effect was present in
the absence of PPN (p = 0.86). In the adjusted interaction
model including clinical prognostic factors and MGMT
status, PPN was borderline nonsignificant (p = 0.063).
Taken together, recognition of an oligodendroglioma-like
component in an otherwise classic GBM identifies a
pathogenetically mixed group without prognostic signifi-
cance. However, the presence of PPN may indicate
biological features of clinical relevance for further
improvement of therapy.
Keywords Glioblastoma  Glioblastoma with
oligodendroglioma-like component  MGMT  IDH1 
EGFR  Pathology  Temozolomide  Randomized trial 
Pseudopalisading necrosis  Prognostic factors
Introduction
The introduction of combined chemo-radiotherapy adding
temozolomide concomitantly and adjuvant to radiotherapy
has modestly increased outcome of patients with newly
diagnosed glioblastoma (GBM) [32], in particular in
patients whose tumors contain an epigenetically inactivated
MGMT gene [11]. However, outcome varies dramatically
even in a homogenously treated patient population with a
median survival of 15 months: 2- and 5-year survival rates
of 27 and 11%, respectively [7, 19, 21, 32]. Histopatho-
logically, GBM is a heterogeneous tumor type and distinct
morphologic subtypes may benefit differently from com-
bined chemo-radiotherapy. Furthermore, unequivocal
separation of GBM and anaplastic astrocytomas from
anaplastic oligo-astrocytic neoplasms is difficult. Previous
reports suggested that distinct morphologic features present
in GBM may have prognostic value, such as the presence
of an oligodendroglioma-like component that was
associated with better outcome in some studies, while the
presence of necrosis has been reported as a negative
prognostic factor [9, 12, 16, 18, 37].
Here, we addressed the question whether particular
morphologic features in GBM can identify clinically
meaningful subgroups in this patient cohort treated hom-
ogenously with combined radio-chemotherapy that has
become the standard of care. A specific goal was to inves-
tigate the clinical relevance of recognition of an
oligodendroglioma-like component in GBM in tumors that
had been diagnosed as GBM (all subtypes) by the initial
local pathology assessment. The histopathological study
was carried out as part of the central review performed in
the phase III EORTC_26981-22981-NCIC_CE.3 trial for
newly diagnosed GBM [32, 33]. The results of this detailed
histopathological review were correlated with outcome and
benefit from the new concomitant chemo-radiotherapy and
in a subset of cases associated with genetic information
including the MGMT methylation status, copy number
aberrations (CNAs) of EGFR, CDK4 and MDM2, combined
loss of chromosomes 1p and 19q, and mutations of IDH1.
Patients and methods
Patients
Patients were enrolled in the phase III EORTC_26981-
22981-NCIC_CE.3 trial [33] (ClinicalTrials.gov, number
NCT00006353) between August 2000 and March 2002.
Eligibility criteria have been detailed elsewhere [32] and
comprised age between 18 and 70 years, histologically
proven newly diagnosed GBM (WHO grade IV) and a
WHO performance status of 0–2. Patients were randomized
to either standard focal radiotherapy (RT) with a total dose
of 60 Gy or concomitant chemotherapy of oral temozolo-
mide (TMZ) at a daily dose of 75 mg/m2 given 7 days per
week during radiotherapy, followed by up to six cycles of
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adjuvant TMZ (150–200 mg/m2) for 5 days every 28 days.
All patients had given written informed consent prior to
entering the study, including for molecular analysis of their
tumors. The study was approved by the local ethics
committees.
Pathology review
Central review was performed jointly by three experienced
neuropathologists (RCJ, KM, PW) according to WHO
2000 criteria [15] using a multiheaded microscope. H&E-
stained full sections were used for the evaluation. In most
cases GFAP-, MIB-1 and a reticulin silver stain were
available (collectively performed in Lausanne). Morpho-
logic features were systematically recorded in a semi-
quantitative manner and comprised cellular differentiation
patterns, types of necrosis (large ischemic type vs. pseud-
opalisading necrosis), microvascular proliferation and
MIB-1 labeling index (see evaluation form, Supplementary
Figure S1). In line with the WHO classification, pseud-
opalisading necrosis (PPN) was defined as irregular, often
serpiginous foci of necrosis surrounded by densely packed,
radially oriented tumor cells. The agreement between the
three pathologists was recorded. For this study, GBM with
an oligodendroglioma-like component (GBM-O) was
defined according to the following histopathological crite-
ria: presence of at least one of two ‘‘major criteria’’—
‘diffuse highly cellular and monotonous growth at low
power magnification’, ‘monomorphous cell population’;
and at least two of three ‘‘minor criteria’’—‘perinuclear
halo formation in tumor cells’, ‘rounded tumor cell nuclei
with dense chromatin pattern’, ‘chickenwire architecture of
tumor microvasculature’. The extent of these features in
the viable tumor tissue was recorded (\25, 25–75,[75%).
GBM with [25% of the tumor tissue showing
oligodendroglioma-like component was subclassified as
GBM-O (see Fig. 1 for some examples).
Tissue microarray, immunohistochemistry
and molecular analysis
Immunohistochemistry for GFAP and MIB-1, and histo-
chemical reticulin staining were performed according to
standard procedures on whole sections. A tissue microarray
(TMA) was constructed comprising 130 patient samples
where tumor blocks with sufficient tissue were available as
reported previously [21]. The TMA was used to screen for
the most common IDH1 mutation (R132H) using the spe-
cific antibody mIDH1R132H (clone H14) [4] and for copy
number aberrations (CNAs) of selected genes by FISH.
FISH for EGFR was performed as described [34]. Two-
color FISH assay was performed using a mixed 1p36/1q25
and 19p13/19q13 dual color probe set (Cat. No 32-231004,
Vysis, Inc., Applied Biosystems, Downers Grove, IL,
USA) as described [31]. Samples showing sufficient FISH
efficiency (*90% nuclei with signals) were evaluated. If
possible, signals were scored in at least 200 non-overlap-
ping, intact nuclei. Deletions of 1p and 19q were scored
when at least 50% of tumor nuclei contained one signal.
The following probes were used for CDK4 and MDM2:
KBI-10725 CD4K/SE12 (12q14); KBI-10717 MDM2/
SE12 (12q15) (Kreatech Diagnostics, Amsterdam; The
Netherlands).
The MGMT methylation status has been determined and
reported previously [11, 32]. Expression of the EGFRvIII
mutant, array comparative genomic hybridization (aCGH)
data and gene expression data were available for a sub-
group of patients [17, 21]. Additional EGFR amplification
data were obtained by quantitative PCR as described [10].
Mutation analysis for IDH1 and IDH2 encompassing codon
Fig. 1 Examples of histology in two tumors diagnosed as glioblas-
toma with oligodendroglioma-like component. a Area showing
diffuse highly cellular and monotonous growth of tumor cells with
a dense chromatin pattern, perinuclear halo formation and chicken-
wire architecture of the microvasculature. b Highly cellular area
showing rounded tumor cell nuclei with dense chromatin pattern and
perinuclear halo formation. See ‘‘Patients and methods’’ for the
definitions used in the present study for recognition of oligodendro-
glioma-like component in glioblastoma. Arrowheads in a mitotic
figures, arrowhead in b florid microvascular proliferation. a,
b Hematoxylin and Eosin staining, original magnification 9200
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132 and 172, respectively, was performed by direct Sanger
sequencing.
Statistics
The Fisher’s exact test (for binary or nominal categorical
data) and the Wilcoxon rank-sum test (for continuous or
ordinal categorical data) were used in the comparisons of
patient and disease characteristics between subgroups.
Survival analyses were performed with Kaplan–Meier
technique with log-rank statistics. The Cox regression was
used for multivariate analyses. All Cox models were fit
with age (B50, 51–60, [60), extent of surgery (total, par-
tial, biopsy only), performance status (0, 1, 2), Mini Mental
Score Examination (\27, 27–30) and MGMT methylation
status (unmethylated, methylated). Pathological features
significant at a 5% level in univariate analyses were
included in the multivariate model. A treatment effect was
assessed using Peto’s heterogeneity test (predictive value).
No adjustment for multiple testing was performed in these
exploratory analyses. SAS version 9.2 was used for sta-
tistical analyses.
Results
Histological diagnosis and subclassification
Central review comprised histological analysis of 360 of
573 patients enrolled (central review of Canadian patients
was performed independently). Baseline characteristics
have been published previously [32] and sub-cohort patient
characteristics are summarized in Supplemental Table S1.
Overall, the patient characteristics of this subset did not
differ significantly from the overall study population, other
than molecular markers that could be determined in patients
who had undergone tumor resection in contrast to biopsy
only. From the total of 360 cases reviewed, 6 were consid-
ered undiagnosable due to insufficient tissue or quality of the
sections. Fifteen (4.2%) tumors did not fulfill the criteria for
GBM and comprised 4 anaplastic astrocytomas (WHO
grade III; AA), 4 anaplastic oligoastrocytomas (WHO grade
III, AOA), 1 anaplastic oligodendroglioma (WHO grade III;
AO), 2 anaplastic ependymomas (WHO grade III), 2 pilo-
cytic astrocytomas with malignant changes, 1 low grade
glioma (WHO grade II) and 1 meningioma. Of the non-
GBM tumors, 6 were in the RT and 9 in the RT/TMZ arm.
The remaining 339 were diagnosed as GBM, of which 3
were subtyped as gliosarcoma and 6 as giant cell GBM.
There was a 95% (338/354) consensus with regard to
diagnosis of GBM versus non-GBM among the three neu-
ropathologists. The median age of patients with confirmed
GBM was 56 years of age (range 19–79) (Supplemental
Table S2).
Frequency of GBM with an oligodendroglioma-like
component
The criteria for GBM-O were met in 52 (15%) samples, at
an expected frequency [12, 29, 37]. Subtyping of centrally
confirmed GBM, including GBM-O, resulted in a 2:1
agreement for 24 cases, of which 16 overlapped with the
debated cases for GBM versus non-GBM. In the group
classified as GBM-O, two of five were considered as AOA
and two as AO, by one of the neuropathologists. The
median age of patients with GBM-O was lower than that of
the other GBM patients (53 vs. 56 years, p = 0.02) (Sup-
plemental Table S2).
GBM-O encompass a pathogenetically heterogeneous
group
Evaluation of important prognostic molecular markers
revealed the same frequency of MGMT methylation in
GBM-O (47%, 16/34) versus the remaining GBM (46%,
60/131) (Table 1). Furthermore, combined loss of 1p/19q,
a hallmark of oligodendroglial tumors and associated with
better prognosis in anaplastic glioma [35], was a rare event,
observed in a single GBM-O, confirmed by aCGH, and one
GBM (Fig. 2; Table 1).
Next, we investigated if GBM-O exhibit a particular
pathogenetic makeup. Mutations of the IDH1 gene that are
Table 1 Tumor genetics of
GBM-O versus GBM
Statistically significant values
are given in bold
a Fisher exact test
Overall cases in central review Confirmed GBM (%) GBM-O (%) GBM (%) p valuea
Alterations
methMGMT 76/165 (46) 16/34 (47) 60/131 (46) 1.00
IDH1 mut 9/130 (7) 6/32 (19) 3/98 (3) 0.007
Co-del 1p/19q 2/137 (1) 1/31 (3) 1/106 (1) 0.4
EGFR amp 70/131 (53) 22/31 (71) 48/100 (48) 0.038
CDK4 amp 24/131 (18) 7/29 (24) 17/102 (17) 0.42
MDM2 amp 13/131 (10) 4/30 (13) 9/101 (9) 0.49
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Fig. 2 Patterns of genetic alterations, diagnosis and outcome. Patient
data for 175 cases with 3/6 genetic tests available were ordered
according to overall survival (OS). Many features are rare, such as
GBM subtypes, or genetic alterations like IDH1 mutations. The
visualization allows identification of patterns of genetic or clinical
features that are enriched in either the short survival group or the long-
term survival group. Gene amplification is represented in red (CDK4,
MDM2, EGFR) and deletions in dark blue (co-deletion of 1p/19q).
Mutation of IDH1 is represented in red, MGMT methylated in gray
and unmethylated in black. OS in months: light green short survival
group (B9 months); green intermediate survival group ([9 and
\24 months); dark green long-term survival group (C24 months).
Age \50 years is represented in gray, 50–60 years in dark gray, and
[60 years in black. Red female, blue male. Pink diagnosis as GBM;
purple GBM-O; yellow Gliosarcoma; orange giant cell GBM (GC-
GBM); blue AOA; green other non-GBM diagnosis. Concordance of
reviewers 3:0 for subtype (Con_subT) or diagnosis (Con_diagn) in
dark blue; blue concordance 2:1; light blue diagnosis by Canadian
central review. Diagnosis of non-GBM is indicated in black. White No
information for all criteria. The associated table below shows the
respective numbers. EGFRvIII information was available for only 56
cases and is not included in the upper panel
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associated with better outcome in GBM [40] were signifi-
cantly enriched in GBM-O (6/32, 19%) as compared to the
remaining GBM (3/98, 3%; p = 0.002). Similarly, EGFR
amplification that has been associated with older age and
potentially worse outcome was present in 71% of GBM-O
(22/31) and 48% of the remaining GBM (48/100)
(p = 0.03). IDH1 and EGFR alterations were mutually
exclusive as reported before [40]. Intriguingly, of 31 GBM-
O for which this genetic information was available, 6
carried the IDH1R132H mutation, 22 displayed an EGFR
amplification, and only three had neither alteration. The
presence of an IDH1 or IDH2 hot-spot mutation other than
IDH1R132H was excluded by direct sequencing in these
three cases. The notion that the GBM-O phenotype iden-
tifies at least two pathogenetically distinct subgroups is
further supported by classification according to the four
gene expression-based subtypes proposed by Verhaak et al.
[36]. Of 14 evaluable GBM-O, 5 grouped with the pro-
neural, 6 with the classical, 2 with the mesenchymal and 1
with the neural GBM subtypes. In accordance with the
reported mutation pattern of the four subgroups, all GBMs
with an IDH1 mutation were in the proneural group, while
most EGFR-amplified and EGFRvIII-positive GBMs were
in the classical subgroup (Fig. 3).
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Fig. 3 Gene expression-based classification and GBM subtype. For
57 patients gene expression data, including for EGFRvIII, was
available from frozen tumor tissue [21]. The tumor samples were
classified according to the algorithm proposed by Verhaak et al. [36]
into classic, mesenchymal, neural and proneural GBM. The samples
are ordered by the gene expression-based classification, followed by
diagnostic subtype, gliosarcoma (GS), GBM-O and GBM. The
respective pathogenetic information and clinical information is the
same as in Fig. 1. The enrichment of specific pathogenetic alterations,
such as IDH1 mutations in the proneural and EGFR amplification and
EGFRvIII expression in the classical subtype, is in accordance with
the report by Verhaak et al. [36]. Gene amplification is represented in
red (CDK4, MDM2, EGFR) and deletions in dark blue (co-deletion of
1p/19q). EGFRvIII expression determined by qRT-PCR is depicted in
yellow. Mutation of IDH1 is represented red, MGMT methylated
in gray and unmethylated in black. OS in months: light green
short survival group (B9 months); green intermediate survival group
([9 and \24 months); dark green long-term survival group
(C24 months). Age \50 is represented in gray, 50–60 in dark gray,
and [60 years in black. Red female, blue male. Pink diagnosis as
GBM; purple GBM-O; yellow gliosarcoma (GS). Concordance of
reviewers 3:0 for subtype (Con_subT) or diagnosis (Con_diagn) in
dark blue; concordance 2:1 in blue; diagnosis by Canadian central
review in light blue. White no information for all criteria
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Survival of patients with GBM-O is not different
from those with GBM
Patients with non-GBM pathology (15/354, 4%) were
enriched in the patient group with overall survival (OS)
exceeding 24 months (9/64, 14%), as compared to the short
survival group (B9 months, 1/101), and the intermediate
group (5/189, 3%) (p \ 0.001, Chi-square-test) (Fig. 1).
Subsequently, only patients with confirmed GBM
(N = 339) are included for further analysis of morphologic
features and outcome. There was no difference in OS
between GBM and GBM-O (logrank test, p = 0.48).
Stratification by age (B50, 51–60 or [60) (p = 0.55) or
MGMT methylation status (p = 0.27) did not differentiate
survival in the two subgroups. When analyzing the GBM-O
separately per randomized treatment arm, survival was not
different for GBM-O in either arm (TMZ/RT ? TMZ arm,
p = 0.81; RT-only arm, p = 0.14) (Fig. 4). The respective
values for progression-free survival were similar
(p = 0.97, TMZ/RT ? TMZ; p = 0.2, RT). Likewise,
using less strict criteria, just the presence of any oligo-
dendroglioma-like component did not show any association
with outcome in either of the two treatment arms (Table 2).
The apparent enrichment of patients with the presence of
any oligodendroglioma-like component in the long survi-
vor group as visualized in Fig. 2 was due to inclusion of
patients where GBM was not confirmed.
Associations of histopathological features
with tumor genetics
The MIB-1 labeling index was significantly higher in
MGMT methylated GBM with a mean index of 38%
(N = 69) as compared to 30% in MGMT unmethylated
tumors (N = 84) (p = 0.0015). A trend for a higher MIB-1
labeling index was associated with IDH1 mutations and
EGFR amplifications (p = 0.07, p = 0.09). No significant
association was observed between any morphologic feature
and the MGMT methylation status.
Associations of tumor genetics and outcome
None of the genetic alterations investigated here was
associated with a prognostic or a predictive value with the
exception of MGMT methylation as previously reported
(Supplementary Table S5) [32, 38]. Mutations of IDH1
were rare in confirmed GBM (9/130; 7%, for which this
information was available) as expected [25] and similarly
distributed between the treatment arms (5, RT; 4,
RT&TMZ), with five of eight assessable cases being
MGMT methylated. These small numbers do not allow
appropriate assessment of the prognostic value of IDH1
mutations (p = 0.7, Supplementary Fig. S2). The patterns
of genetic alterations and outcome are displayed in Fig. 2.
Presence of pseudopalisading necroses (PPN) is
associated with a treatment effect of TMZ
Correlation of the distinct morphologic features assessed,
such as type of necrosis, vascular pattern and cell differ-
entiation, and including the MIB-1 (Ki67) labeling index
(Supplementary Fig. S1), identified PPN as the only mor-
phologic feature associated with outcome (Table 2). PPN
was present in 63% of all GBM (212/339) and associated
with a treatment effect (Fig. 5; Table 2). Addition of TMZ
to RT was beneficial in the patient cohort exhibiting PPN
(p = 0.0002), while no such effect was present in the
absence of PPN (p = 0.86; Fig. 5a). Peto’s interaction test
was significant (p = 0.026; Fig. 5b) and borderline non-
significant in a Cox interaction model adjusted for known
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Fig. 4 GBM-O did not have better prognosis than all other GBMs. Kaplan–Meier curves show the OS of GBM versus GBM-O in the RT arm
(log-rank test p = 0.136) (a) and the TMZ/RT ? TMZ arm (p = 0.814) (b)
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Table 2 Morphologic features of confirmed GBM and OS (N = 339)
Subsample characteristics Treatment p value
Fisher
Prognostic value for overall survival p value
RT (N = 173)
N (%)
TMZ/RT (N = 166)
N (%)
Total (N = 339)
N (%)
Pooled RT TMZ/RT
Diagnosis
Glioblastoma 145 (83.8) 133 (80.1) 278 (82.0) 0.69
GBM-O 25 (14.5) 27 (16.3) 52 (15.3)
Giant cell glioblastoma 2 (1.2) 4 (2.4) 6 (1.8)
Gliosarcoma 1 (0.6) 2 (1.2) 3 (0.9)
GBM confirmed
GBM 148 (85.5) 139 (83.7) 287 (84.7) 0.65 0.48 0.14 0.81
GBM-O 25 (14.5) 27 (16.3) 52 (15.3)
NECROSIS—large ischemic type
No 34 (19.7) 23 (13.9) 57 (16.8) 0.19 0.79 0.18 0.20
Yes 139 (80.3) 143 (86.1) 282 (83.2)
NECROSIS—pseudopalisading
No 62 (35.8) 65 (39.2) 127 (37.5) 0.58 0.27 0.32 0.03
Yes 111 (64.2) 101 (60.8) 212 (62.5)
NECROSIS—thrombosed vessels
No 27 (15.6) 28 (16.9) 55 (16.2) 0.77 0.48 0.99 0.40
Yes 146 (84.4) 138 (83.1) 284 (83.8)
Microvascular proliferation
No 2 (1.2) 4 (2.4) 6 (1.8) 0.44 0.80 0.98 0.92
Yes 171 (98.8) 162 (97.6) 333 (98.2)
Perivascular lymph
No 133 (76.9) 128 (77.1) 261 (77.0) 0.90 0.89 0.39 0.40
Yes 38 (22.0) 35 (21.1) 73 (21.5)
Missing 2 (1.2) 3 (1.8) 5 (1.5)
Oligodendroglioma-like component
No 129 (74.6) 120 (72.3) 249 (73.5) 0.80 0.24 0.29 0.52
Yes 44 (25.4) 44 (26.5) 88 (26.0)
Missing 0 (0.0) 2 (1.2) 2 (0.6)
Sarcomatous comp
No 167 (96.5) 157 (94.6) 324 (95.6) 0.57 0.15 0.16 0.34
Yes 5 (2.9) 7 (4.2) 12 (3.5)
Missing 1 (0.6) 2 (1.2) 3 (0.9)
Multinucleated giant cells
No 137 (79.2) 124 (74.7) 261 (77.0) 0.44 0.43 0.78 0.38
Yes 36 (20.8) 40 (24.1) 76 (22.4)
Missing 0 (0.0) 2 (1.2) 2 (0.6)
Gemistocytic cells
No 124 (71.7) 123 (74.1) 247 (72.9) 0.54 0.41 0.70 0.65
Yes 49 (28.3) 41 (24.7) 90 (26.5)
Missing 0 (0.0) 2 (1.2) 2 (0.6)
Other prominent patterns
No 157 (90.8) 141 (84.9) 298 (87.9) 0.21 0.82 0.13 0.75
Yes 14 (8.1) 20 (12.0) 34 (10.0)
Missing 2 (1.2) 5 (3.0) 7 (2.1)
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clinical prognostic factors (p = 0.087, Supplemental Table
S3) not accounting for MGMT that was available only for a
subset of 165 mostly resected tumors (Supplementary
Table S1). This suggests that indeed PPN may identify a
subgroup of chemo-sensitive GBM. The incidence of PPN
was lower in patients with biopsy only (46 vs. 65.4%,
p = 0.01), while no association with age was observed
(p = 0.15). To exclude a bias of potential underestimation
of PPN in stereotactic biopsies resulting from the small
sample size, and the fact that biopsy only by itself is an
unfavorable prognostic factor, the analyses were repeated
in patients who underwent a tumor resection. Peto’s test
P=0.002
P=0.86
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0 1 2 3 4 5 6
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk: Treatment and feature
61 62 31 9 2 0 0
109 111 55 9 2 2 1
63 65 36 8 3 2 1
92 101 60 29 14 6 3
RT/no PPN
RT/PPN
TMZ-RT/no PPN
TMZ-RT/PPN
P=0.0015 (df=3)
a
b
Fig. 5 The presence of pseudo-
palisading necrosis is associated
with a treatment effect. a The
Kaplan–Meier curves visualize
the overall outcome of the
patients in the presence or
absence of pseudo-palisading
necrosis (PPN). In the presence
of PPN, there is a treatment
effect (RT vs. TMZ/
RT ? TMZ p = 0.002), while
in the absence of PPN, no such
difference is observed (RT vs.
TMZ/RT ? TMZ, p = 0.86).
b Forest Plot and Peto’s test of
interaction between PPN and
treatment for OS in all
confirmed GBMs. Peto’s test
was significant (p = 0.03)
indicating that treatment effects
differ significantly as a function
of PPN
Table 2 continued
Subsample characteristics Treatment p value
Fisher
Prognostic value for overall survival p value
RT (N = 173)
N (%)
TMZ/RT (N = 166)
N (%)
Total (N = 339)
N (%)
Pooled RT TMZ/RT
MIB-1
Median 30.0 30.0 30.0 0.08a 0.13 0.65 0.24
Mean (SD) 32.72 (17.81) 36.40 (18.26) 34.53 (18.10)
Range 5.0–80.0 5.0–90.0 5.0–90.0
N obs 156 150 306
Statistically significant values are given in bold
a Wilcoxon rank-sum test
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was significant (p = 0.040, Supplementary Fig. S3) and the
adjusted Cox interaction model including MGMT was
borderline nonsignificant (p = 0.063, Supplementary
Table S4). A similar treatment effect of PPN was observed
for PFS (p \ 0.0001) in the TMZ arm, while there was a
trend in the RT arm (p = 0.078).
Discussion
The present study was performed to assess prognostic
significance of morphological features of GBM in the
registration trial for temozolomide, with a focus on GBM-
O. Classification of GBM was in high concordance ([95%)
between the 59 centers and central review. Expectedly,
reclassification as a non-GBM histology was significantly
enriched among long-term survivors (Fig. 2). The trial
analyses and respective reports were on an intention-to-
treat basis [32], and hence include patients with non-GBM
histology.
Identification of unambiguous morphologic features
with a prognostic or predictive value within GBM would
be clinically valuable, as such markers could be easily
implemented in routine histopathologic diagnostics. The
recognized phenotypical GBM variants, giant cell GBM
and gliosarcoma are rare (6,\2% and 3,\1% in this study)
[15], precluding reliable assessment of a potential prog-
nostic significance when patients are treated with the
current standard of care. Evaluation of the prognostic value
of an oligodendroglioma-like component in an otherwise
classic GBM revealed no association with a more favorable
disease course in either of the two treatment arms, in
contrast to previous studies on GBM-O [9, 12, 16, 18, 29].
This discrepancy might be explained by the fact that most
studies were performed in the pre-TMZ chemotherapy era.
GBM-O, as defined in this report, seems to benefit simi-
larly from chemoradiotherapy, in line with the identical
MGMT methylation frequency compared to other GBMs
that differ from frequencies reported for AO and AOA of
over 70% [5, 20, 27, 39]. Further, the delineation of ‘‘pure’’
GBM versus GBM-O, and AOA and AO is difficult, as
reflected in variable frequencies of reported 1p/19q co-
deletions in these studies ranging from 0 to over 20% for
the GBM-O subgroup [9, 12, 13, 16, 18, 29].
This study uncovered that GBM-O encompasses at least
two distinct pathogenetic subgroups, characterized either
by EGFR amplifications or IDH1 mutations, and further
supported by respective expression-based classification
(Fig. 3). GBM-O, as defined here, may in part overlap with
the small cell variant of GBM with high cellularity, diffuse
more or less monotonous growth and relatively small,
partly rounded nuclei that is known for increased EGFR
amplification frequencies [12, 18]. Conversely, GBM with
IDH mutations are now recognized as a distinct subtype
with a different pathogenetic/epigenetic origin, evolving
from lower grade glioma with high frequencies of IDH
mutations, characteristic of secondary GBM [1, 23, 40].
Interestingly, IDH mutant gliomas are associated with a
DNA hypermethylation phenotype [24]. This association
has recently also been reported in leukemia, identifying a
new prognostic subtype, and mechanistically linking
aberrant metabolism (onco-metabolite) with epigenetic
deregulation [6, 26]. Our finding that recognition of an
oligodendroglioma-like phenotype in otherwise classic
GBM associates two completely different genetic/epige-
netic GBM subtypes is a surprise and questions the clinical
utility of morphologic identification of GBM-O. The
introduction in the 2007 WHO classification of high-grade
malignant oligoastrocytic tumors with necrosis as GBM-O
[14] has led to substantial controversy among pathologists
[30] and will certainly have to be re-visited given the
recently discovered distinct pathogenetic/epigenetic evo-
lution. Determination of oncogenetic events such as IDH
status and 1p/19q co-deletions provide a more promising
tool for robust and reproducible (sub) classification of
malignant gliomas [8].
Evaluation of distinct morphologic features in this
homogenously treated patient population identified PPN as
potentially associated with benefit from combined chemo-
radiotherapy. Presence of PPN may reflect the tumor milieu
including the tumor vascularization type, which may have
an effect on drug perfusion and thereby on response to
chemotherapy. Pseudopalisades are enriched for hypoxic
and apoptotic tumor cells, with a lower relative prolifera-
tion index, and are frequently associated with a central
degenerating or thrombosed vascular lumen [2, 28].
Tumor-associated vascular injury has been associated with
factors released from glioma cells after genetic alterations
such as EGFR amplifications or cellular stress conditions
such as hypoxia [3, 28]. Based on a comprehensive anal-
ysis of PPN in human GBM and experimental models, it
has been hypothesized that pseudopalisades comprise
hypoxic tumor cells migrating away from dysfunctional
vessels [2, 28]. However, the presence of PPN does not
directly correlate with hypoxia as suggested by gene
expression profiles available for 50 patients of this cohort
[21, 22]. No correlation was observed with the previously
identified hypoxia-induced gene expression signature,
while the EGFR expression signature (G25) was signifi-
cantly associated with the presence of PPN (p = 0.02).
Evaluation of associations of PPN with previously identi-
fied expression signatures in appropriately powered studies
may indicate underlying molecular mechanisms that merit
further analysis for improvement of therapy. The respective
hypotheses may be tested in the database of ‘The Cancer
Genome Atlas’ (TCGA) once the morphologic information
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is publicly available [36]. In contrast to our study, Homma
et al. [12] reported an association of the presence of any
type of necrosis with worse outcome. This discrepancy
may be explained by the fact that all these patients were
treated before the TMZ era (before 1994) and likely
received RT alone.
This study has shown that systematic combined mor-
phologic and molecular characterization of tumor samples
of patients enrolled in clinical trials is instrumental for
validating and identifying new prognostic and predictive
factors that will have an impact on clinical practice. This
was an exploratory study requiring validation in an inde-
pendent data set of a homogenous patient population
treated with combined chemo-radiotherapy. The limited
numbers of samples available for molecular analyses
unfortunately reduced the power of the study, once more
emphasizing the importance of collecting sufficient tissues
for all patients enrolled in clinical trials.
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